|Articles|August 15, 2002
Another application: Lens approved for therapy; CIBA helps fire victims
Atlanta-CIBA Vision's Focus Night & Day 30-day contact lenses will be marketed throughout Europe after receiving the CE Mark for therapeutic use.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5











































.png)


